FDA Clearance Tracker · P000058-S088
Infuse Bone Graft
Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Aug 25, 2023
Approved
Time to decision
87 days
Received May 30, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P000058-S088
- Device name
- Infuse Bone Graft
- Applicant
- Medtronic Sofamor Danek USA, Inc.
- Applicant location
- Memphis, TN
- Received
- May 30, 2023
- Decided
- Aug 25, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P000058
Device type
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for expansion of the approved indications for use of INFUSE® Bone Graft to include implantation with additional interbody fusion devices, a subset of the Anteralign Spinal System with Titan NanoLOCK Surface Technology, specifically the specified sizes of the Anteralign LS and TL systems, utilizing select open surgical procedures in conjunction with supplemental spinal fixation hardware or alone.
Source documents
Other decisions for Medtronic Sofamor Danek USA, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262572 · Decided Oct 29, 2026 · 94 days after receipt
Device type: Intervertebral Fusion Device With Bone Graft, Lumbar (MAX) · Orthopedic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.